121 related articles for article (PubMed ID: 6230516)
21. [Chemotherapy of metastatic soft tissue sarcoma].
Le Cesne A
Presse Med; 1995 Sep; 24(26):1214-20. PubMed ID: 7567851
[TBL] [Abstract][Full Text] [Related]
22. High-dose ifosfamide in bone and soft tissue sarcomas: results of phase II and pilot studies--dose-response and schedule dependence.
Patel SR; Vadhan-Raj S; Papadopolous N; Plager C; Burgess MA; Hays C; Benjamin RS
J Clin Oncol; 1997 Jun; 15(6):2378-84. PubMed ID: 9196153
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of anguidine in patients with sarcomas unresponsive to prior chemotherapy: A Southwest Oncology Group Study.
Thigpen JT; Vaughn C; Stuckey WJ
Cancer Treat Rep; 1981; 65(9-10):881-2. PubMed ID: 7273022
[No Abstract] [Full Text] [Related]
24. Phase II study of nimustine in metastatic soft tissue sarcoma. European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Wagener DJ; Somers R; Santoro A; Verweij J; Woll PJ; Blackledge G; Schütte HJ; Lentz MA; van Glabbeke M
Eur J Cancer; 1991; 27(12):1604-5. PubMed ID: 1782068
[TBL] [Abstract][Full Text] [Related]
25. A randomized study of continuous infusion vindesine versus vinblastine in adults with refractory metastatic sarcomas.
Yap BS; Benjamin RS; Plager C; Burgess MA; Papadoupoulos N; Bodey GP
Am J Clin Oncol; 1983 Apr; 6(2):235-8. PubMed ID: 6829497
[TBL] [Abstract][Full Text] [Related]
26. A phase II study of chlorozotocin in advanced large bowel carcinoma. A cooperative study between two institutions.
Schutt AJ; Hoth D; Moertel CG; Schein PS; Rubin J; O'Connell MJ
Am J Clin Oncol; 1984 Oct; 7(5):507-11. PubMed ID: 6239538
[TBL] [Abstract][Full Text] [Related]
27. Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G; D'Ambrosio L; Pignochino Y; Palmerini E; Zucchetti M; Boccone P; Aliberti S; Stacchiotti S; Bertulli R; Piana R; Miano S; Tolomeo F; Chiabotto G; Sangiolo D; Pisacane A; Dei Tos AP; Novara L; Bartolini A; Marchesi E; D'Incalci M; Bardelli A; Picci P; Ferrari S; Aglietta M
Lancet Oncol; 2018 Oct; 19(10):1360-1371. PubMed ID: 30217671
[TBL] [Abstract][Full Text] [Related]
28. Ifosfamide plus epirubicin at escalating doses in the treatment of locally advanced and/or metastatic sarcomas.
Toma S; Palumbo R; Canavese G; Albanese E; Cantoni E; Barisone A; Reggiardo G; Rosso R; Santi L
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S222-7. PubMed ID: 8453703
[TBL] [Abstract][Full Text] [Related]
29. Phase II trial of Baker's antifol in metastatic sarcoma.
Thigpen JT; O'Bryan RM; Benjamin RS; Coltman CA
Cancer Treat Rep; 1977 Nov; 61(8):1485-7. PubMed ID: 922752
[TBL] [Abstract][Full Text] [Related]
30. Phase I evaluation of chlorozotocin: single dose every six weeks.
Taylor S; Belt RJ; Haas CD; Stephens RL; Hoogstraten B
Cancer; 1980 Dec; 46(11):2365-8. PubMed ID: 6449279
[TBL] [Abstract][Full Text] [Related]
31. Aclacinomycin A. Phase II evaluation in advanced soft tissue sarcoma.
Pazdur R; Samson MK; Baker LH
Am J Clin Oncol; 1987 Jun; 10(3):237-9. PubMed ID: 3473924
[TBL] [Abstract][Full Text] [Related]
32. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas.
Maki RG; Kraft AS; Scheu K; Yamada J; Wadler S; Antonescu CR; Wright JJ; Schwartz GK
Cancer; 2005 Apr; 103(7):1431-8. PubMed ID: 15739208
[TBL] [Abstract][Full Text] [Related]
33. Chlorozotocin: results in colorectal carcinoma treated with high and low doses. A Southwest Oncology Group study.
Haas CD; McCracken JD; Vaughn CB; Stephens RL; Bukowski RM; Eyre HJ
Invest New Drugs; 1984; 2(4):401-4. PubMed ID: 6239836
[TBL] [Abstract][Full Text] [Related]
34. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone Sarcoma Group.
Schütte J; Mouridsen HT; Stewart W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Eur J Cancer; 1990; 26(5):558-61. PubMed ID: 2144740
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of dianhydrogalactitol in advanced soft tissue and bony sarcomas: a Southwest Oncology Group study.
Thigpen JT; Samson MK
Cancer Treat Rep; 1979 Apr; 63(4):553-5. PubMed ID: 445509
[No Abstract] [Full Text] [Related]
36. The role of mTOR inhibitors for treatment of sarcomas.
Mita MM; Tolcher AW
Curr Oncol Rep; 2007 Jul; 9(4):316-22. PubMed ID: 17588357
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of diaziquone in anthracycline-resistant adult soft tissue and bone sarcoma patients: a Southeastern Cancer Study Group Trial.
Chan C; Bartolucci A; Brenner D; Presant C; Davila E; Carpenter J; Greco FA; Clamon G; Moore J
Cancer Treat Rep; 1986 Mar; 70(3):427-8. PubMed ID: 3456834
[No Abstract] [Full Text] [Related]
38. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
[TBL] [Abstract][Full Text] [Related]
39. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
40. Preclinical and clinical studies on chlorozotocin, a new nitrosourea with decreased bone marrow toxicity.
Macdonald JS; Hoth D; Schein PS
Recent Results Cancer Res; 1980; 70():83-9. PubMed ID: 6444466
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
